Abstract
Neoadjuvant chemotherapy (NAC) may lead to successful margin-negative resection (R0) in patients with borderline resectable pancreatic head cancer (BRPHC). NAC using a metallic stent has been attempted in patients with BRPHC, however, the efficacy of this therapy and the influence of use of a covered self-expanding metal stent (CSEMS) for its delivery in the treatment of BRPHC has not been evaluated yet.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
